Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape

Expert Review of Hematology

Volumn 9, Issue 8, 2016, Pages 719-721

  Turtle, Cameron J ^a,b   Maloney, David G ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute lymphoblastic leukemia; cellular therapy; Chimeric antigen receptor; chronic lymphocytic leukemia; immunotherapy; non Hodgkin lymphoma; T cells

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; LYMPHOCYTE ANTIGEN RECEPTOR; RCVRN PROTEIN, HUMAN; RECOVERIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL TRIAL (TOPIC); EDITORIAL; GENE TRANSFER; HUMAN; LYMPHOCYTE ACTIVATION; MINIMAL RESIDUAL DISEASE; PRECLINICAL STUDY; PRIORITY JOURNAL; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY;

ANTIGENS, CD19; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL; RECOVERIN;

EID: 84976897911     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2016.1203251     Document Type: Editorial

References (20)

1. C.J.Turtle Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol. 2014;99(2):132–140.
2. M.L.Davila, I.Riviere, X.Wang, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
3. S.A.Grupp, M.Kalos, D.Barrett, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
4. J.N.Kochenderfer, M.E.Dudley, S.H.Kassim, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–549.
5. D.W.Lee, J.N.Kochenderfer, M.Stetler-Stevenson, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
6. S.L.Maude, N.Frey, P.A.Shaw, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
7. D.L.Porter, B.L.Levine, M.Kalos, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
8. D.L.Porter, W.T.Hwang, N.V.Frey, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
9. C.J.Turtle, L.A.Hanafi, C.Berger, et al. CD19 CAR-T cells of defined CD4+:CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138.
10. C.Carpenito, M.C.Milone, R.Hassan, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106(9):3360–3365.
11. M.Hudecek, M.T.Lupo-Stanghellini, P.L.Kosasih, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153–3164.
12. M.Hudecek, D.Sommermeyer, P.L.Kosasih, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135.
13. M.Jonnalagadda, A.Mardiros, R.Urak, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757–768.
14. B.Savoldo, C.A.Ramos, E.Liu, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–1826.
15. D.Sommermeyer, M.Hudecek, P.L.Kosasih, et al. Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia. 2015;30(2):492–500.
16. X.Wang, L.L.Popplewell, J.R.Wagner, et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980–2990.
17. J.N.Brudno, R.P.Somerville, V.Shi, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–1121.
18. N.Cieri, B.Camisa, F.Cocchiarella, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573–584.
19. L.Gattinoni, E.Lugli, Y.Ji, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–1297.
20. L.Gattinoni, S.E.Finkelstein, C.A.Klebanoff, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–912.